New hope for melanoma brain tumors: triple-drug combo enters human trials
NCT ID NCT06194929
First seen Jan 04, 2026 · Last updated Apr 30, 2026 · Updated 17 times
Summary
This study tests two or three drugs (defactinib, avutometinib, and possibly encorafenib) in people with advanced melanoma that has spread to the brain. The goal is to see if these combinations can shrink brain tumors and are safe. About 33 adults whose melanoma has gotten worse after standard immunotherapy will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRAIN METASTASES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Huntsman Cancer Institute
RECRUITINGSalt Lake City, Utah, 84112, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Iowa
RECRUITINGIowa City, Iowa, 52242, United States
Contact Phone: •••-•••-••••
Contact
Conditions
Explore the condition pages connected to this study.